Loading...
•
Sep 30, 2023
Co-Diagnostics Q3 2023 Earnings Report
Reported financial results for the quarter ended September 30, 2023.
Key Takeaways
Co-Diagnostics reported total revenue of approximately $2.5 million in the third quarter of 2023, including $2.3 million in grant revenue. The company is progressing in the development of other test indications beyond Covid-19 for the new platform: TB, multiplex respiratory, and HPV.
Reported $2.5 million in total revenue for Q3 2023.
Grant revenue contributed $2.3 million to the total revenue.
Expects to finalize an EUA submission to the FDA for the COVID-19 test on Co-Dx PCR platform by year-end.
Progressing in the development of other test indications beyond Covid-19 for the new platform: TB, multiplex respiratory, and HPV.
Revenue by Segment
Forward Guidance
Co-Diagnostics anticipates the new platform will serve as the foundation for future development initiatives and believes that its patented Co-Primers™ technology allows for reliable, affordable high-quality test results.
Positive Outlook
- The company expects to finalize an EUA submission to the FDA for the COVID-19 test on our Co-Dx PCR platform by year-end.
- The company anticipates its new platform will serve as the foundation for Co-Diagnostics’ future development initiatives.
- The company believes that its patented Co-Primers™ technology allows for reliable, affordable high-quality test results.
- The company looks forward to delivering its unique platform to the market.
- The company believes in the potential for the new platform to have a transformative effect on diagnostics worldwide.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...